vs
NATURES SUNSHINE PRODUCTS INC（NATR）とPREFORMED LINE PRODUCTS CO（PLPC）の財務データ比較。上の社名をクリックして会社を切り替えられます
PREFORMED LINE PRODUCTS COの直近四半期売上が大きい（$173.1M vs $123.8M、NATURES SUNSHINE PRODUCTS INCの約1.4倍）。PREFORMED LINE PRODUCTS COの純利益率が高く（4.9% vs 3.3%、差は1.6%）。NATURES SUNSHINE PRODUCTS INCの前年同期比売上増加率が高い（4.7% vs 3.6%）。PREFORMED LINE PRODUCTS COの直近四半期フリーキャッシュフローが多い（$11.8M vs $7.6M）。過去8四半期でPREFORMED LINE PRODUCTS COの売上複合成長率が高い（10.8% vs 5.6%）
Natures Sunshine Products, Inc.（通称NSP）は、ハーブ、ビタミン、ミネラルを含む栄養補助食品やスキンケアなどのパーソナルケア製品の製造を行っています。本社はユタ州リーハイに置き、同州スパニッシュフォークに生産拠点を構えています。
プリフォームド・ライン・プロダクツ社（PLPC）は、送配電、通信、再生可能エネルギーインフラ分野向けのエンジニアリングハードウェアや部品を設計・製造・供給し、世界各国の事業者にネットワークの信頼性と業務効率を高めるソリューションを提供している。
NATR vs PLPC — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $123.8M | $173.1M |
| 純利益 | $4.1M | $8.4M |
| 粗利率 | 72.5% | 29.8% |
| 営業利益率 | 4.3% | 6.8% |
| 純利益率 | 3.3% | 4.9% |
| 売上前年比 | 4.7% | 3.6% |
| 純利益前年比 | 1379.4% | -19.3% |
| EPS（希薄化後） | $0.23 | $1.72 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $123.8M | $173.1M | ||
| Q3 25 | $128.3M | $178.1M | ||
| Q2 25 | $114.8M | $169.6M | ||
| Q1 25 | $113.2M | $148.5M | ||
| Q4 24 | $118.2M | $167.1M | ||
| Q3 24 | $114.6M | $147.0M | ||
| Q2 24 | $110.6M | $138.7M | ||
| Q1 24 | $111.0M | $140.9M |
| Q4 25 | $4.1M | $8.4M | ||
| Q3 25 | $5.3M | $2.6M | ||
| Q2 25 | $5.3M | $12.7M | ||
| Q1 25 | $4.7M | $11.5M | ||
| Q4 24 | $-321.0K | $10.5M | ||
| Q3 24 | $4.3M | $7.7M | ||
| Q2 24 | $1.3M | $9.4M | ||
| Q1 24 | $2.3M | $9.6M |
| Q4 25 | 72.5% | 29.8% | ||
| Q3 25 | 73.3% | 29.7% | ||
| Q2 25 | 71.7% | 32.7% | ||
| Q1 25 | 72.1% | 32.8% | ||
| Q4 24 | 72.0% | 33.3% | ||
| Q3 24 | 71.3% | 31.1% | ||
| Q2 24 | 71.4% | 31.9% | ||
| Q1 24 | 71.2% | 31.3% |
| Q4 25 | 4.3% | 6.8% | ||
| Q3 25 | 7.0% | 7.4% | ||
| Q2 25 | 3.7% | 10.1% | ||
| Q1 25 | 5.4% | 8.8% | ||
| Q4 24 | 3.8% | 10.5% | ||
| Q3 24 | 4.6% | 7.1% | ||
| Q2 24 | 5.1% | 8.1% | ||
| Q1 24 | 4.2% | 8.2% |
| Q4 25 | 3.3% | 4.9% | ||
| Q3 25 | 4.2% | 1.5% | ||
| Q2 25 | 4.6% | 7.5% | ||
| Q1 25 | 4.2% | 7.8% | ||
| Q4 24 | -0.3% | 6.3% | ||
| Q3 24 | 3.8% | 5.2% | ||
| Q2 24 | 1.2% | 6.8% | ||
| Q1 24 | 2.1% | 6.8% |
| Q4 25 | $0.23 | $1.72 | ||
| Q3 25 | $0.30 | $0.53 | ||
| Q2 25 | $0.28 | $2.56 | ||
| Q1 25 | $0.25 | $2.33 | ||
| Q4 24 | $-0.02 | $2.13 | ||
| Q3 24 | $0.23 | $1.54 | ||
| Q2 24 | $0.07 | $1.89 | ||
| Q1 24 | $0.12 | $1.94 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $93.9M | — |
| 総負債低いほど良い | — | $38.3M |
| 株主資本純資産 | $161.6M | $475.5M |
| 総資産 | $261.1M | $653.6M |
| 負債/資本比率低いほどレバレッジが低い | — | 0.08× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $93.9M | — | ||
| Q3 25 | $95.6M | — | ||
| Q2 25 | $81.3M | — | ||
| Q1 25 | $86.5M | — | ||
| Q4 24 | $84.7M | — | ||
| Q3 24 | $78.7M | — | ||
| Q2 24 | $68.7M | — | ||
| Q1 24 | $77.8M | — |
| Q4 25 | — | $38.3M | ||
| Q3 25 | — | $36.0M | ||
| Q2 25 | — | $31.8M | ||
| Q1 25 | — | $29.1M | ||
| Q4 24 | — | $20.8M | ||
| Q3 24 | — | $27.2M | ||
| Q2 24 | — | $31.6M | ||
| Q1 24 | $2.1M | $55.0M |
| Q4 25 | $161.6M | $475.5M | ||
| Q3 25 | $166.7M | $466.3M | ||
| Q2 25 | $163.7M | $460.7M | ||
| Q1 25 | $167.1M | $435.8M | ||
| Q4 24 | $161.0M | $422.3M | ||
| Q3 24 | $162.6M | $429.0M | ||
| Q2 24 | $156.4M | $416.2M | ||
| Q1 24 | $159.7M | $413.4M |
| Q4 25 | $261.1M | $653.6M | ||
| Q3 25 | $264.8M | $644.6M | ||
| Q2 25 | $254.9M | $631.5M | ||
| Q1 25 | $252.7M | $592.5M | ||
| Q4 24 | $240.9M | $573.9M | ||
| Q3 24 | $245.3M | $592.0M | ||
| Q2 24 | $235.8M | $572.6M | ||
| Q1 24 | $247.3M | $586.1M |
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.08× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | 0.01× | 0.13× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $9.9M | $21.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $7.6M | $11.8M |
| FCFマージンFCF / 売上 | 6.1% | 6.8% |
| 設備投資強度設備投資 / 売上 | 1.9% | 5.9% |
| キャッシュ転換率営業CF / 純利益 | 2.41× | 2.60× |
| 直近12ヶ月FCF直近4四半期 | $28.8M | $33.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $9.9M | $21.9M | ||
| Q3 25 | $18.5M | $18.9M | ||
| Q2 25 | $4.3M | $26.9M | ||
| Q1 25 | $2.6M | $5.7M | ||
| Q4 24 | $12.2M | $24.1M | ||
| Q3 24 | $9.6M | $9.4M | ||
| Q2 24 | $1.3M | $28.3M | ||
| Q1 24 | $2.2M | $5.8M |
| Q4 25 | $7.6M | $11.8M | ||
| Q3 25 | $16.8M | $8.3M | ||
| Q2 25 | $3.0M | $18.6M | ||
| Q1 25 | $1.5M | $-5.3M | ||
| Q4 24 | $10.0M | $20.6M | ||
| Q3 24 | $7.9M | $5.8M | ||
| Q2 24 | $-2.0M | $24.6M | ||
| Q1 24 | $-1.5M | $1.8M |
| Q4 25 | 6.1% | 6.8% | ||
| Q3 25 | 13.1% | 4.7% | ||
| Q2 25 | 2.6% | 10.9% | ||
| Q1 25 | 1.3% | -3.6% | ||
| Q4 24 | 8.5% | 12.3% | ||
| Q3 24 | 6.9% | 3.9% | ||
| Q2 24 | -1.9% | 17.7% | ||
| Q1 24 | -1.4% | 1.3% |
| Q4 25 | 1.9% | 5.9% | ||
| Q3 25 | 1.3% | 6.0% | ||
| Q2 25 | 1.2% | 4.9% | ||
| Q1 25 | 1.0% | 7.4% | ||
| Q4 24 | 1.9% | 2.1% | ||
| Q3 24 | 1.5% | 2.4% | ||
| Q2 24 | 3.0% | 2.7% | ||
| Q1 24 | 3.3% | 2.8% |
| Q4 25 | 2.41× | 2.60× | ||
| Q3 25 | 3.46× | 7.21× | ||
| Q2 25 | 0.81× | 2.12× | ||
| Q1 25 | 0.55× | 0.49× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | 2.21× | 1.22× | ||
| Q2 24 | 0.97× | 3.02× | ||
| Q1 24 | 0.94× | 0.60× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
PLPC
セグメントデータなし
